Inflammation Research

, Volume 59, Issue 1, pp 1–14

Gatekeepers of intestinal inflammation

Review

Abstract

The intestine is subjected to a barrage of insults from food, bacterial flora, and pathogens. Despite this constant antigenic challenge, the mucosal tissues lining the intestinal tract remain largely under control. The mechanisms regulating the homeostatic balance in the gut have been investigated for many years by many groups, but the precise nature of the regulatory control remains elusive. In this review, we provide an overview of pathways proposed to be involved in dampening the inflammatory response and maintaining the homeostatic balance in the intestine, and how these pathways may be disrupted in ulcerative colitis and Crohn’s disease.

Keywords

Costimulatory receptors Defensins IBD Immunomodulators Cytokines 

References

  1. 1.
    Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol. 2003;3:331–41.PubMedCrossRefGoogle Scholar
  2. 2.
    Hayday A, Viney JL. The ins and outs of body surface immunology. Science. 2000;290:97–100.PubMedCrossRefGoogle Scholar
  3. 3.
    Bilsborough J, Viney JL. Gastrointestinal dendritic cells play a role in immunity, tolerance, and disease. Gastroenterology. 2004;127:300–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Coombes JL, Powrie F. Dendritic cells in intestinal immune regulation. Nat Rev Immunol. 2008;8:435–46.PubMedCrossRefGoogle Scholar
  5. 5.
    Kelsall BL. A focus on dendritic cells and macrophages as key regulators of mucosal immunity. Mucosal Immunol. 2008;1:423–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Kelsall BL, Rescigno M. Mucosal dendritic cells in immunity and inflammation. Nat Immunol. 2004;5:1091–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Rescigno M, Lopatin U, Chieppa M. Interactions among dendritic cells, macrophages, and epithelial cells in the gut: implications for immune tolerance. Curr Opin Immunol. 2008;20:669–75.PubMedCrossRefGoogle Scholar
  8. 8.
    Viney JL, Mowat AM, O’Malley JM, Williamson E, Fanger NA. Expanding dendritic cells in vivo enhances the induction of oral tolerance. J Immunol. 1998;160:5815–25.PubMedGoogle Scholar
  9. 9.
    Rescigno M, Urbano M, Valzasina B, Francolini M, Rotta G, Bonasio R, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol. 2001;2:361–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Iwasaki A, Kelsall BL. Unique functions of CD11b+, CD8 alpha+, and double-negative Peyer’s patch dendritic cells. J Immunol. 2001;166:4884–90.PubMedGoogle Scholar
  11. 11.
    Iwasaki A, Kelsall BL. Freshly isolated Peyer’s patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells. J Exp Med. 1999;190:229–39.PubMedCrossRefGoogle Scholar
  12. 12.
    Williamson E, Bilsborough JM, Viney JL. Regulation of mucosal dendritic cell function by receptor activator of NF-kappa B (RANK)/RANK ligand interactions: impact on tolerance induction. J Immunol. 2002;169:3606–12.PubMedGoogle Scholar
  13. 13.
    Bilsborough J, George TC, Norment A, Viney JL. Mucosal CD8alpha+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties. Immunology. 2003;108:481–92.PubMedCrossRefGoogle Scholar
  14. 14.
    Morrissey PJ, Charrier K, Braddy S, Liggitt D, Watson JD. CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells. J Exp Med. 1993;178:237–44.PubMedCrossRefGoogle Scholar
  15. 15.
    Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity. 1994;1:553–62.PubMedCrossRefGoogle Scholar
  16. 16.
    Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med. 1999;190:995–1004.PubMedCrossRefGoogle Scholar
  17. 17.
    Powrie F, Carlino J, Leach MW, Mauze S, Coffman RL. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med. 1996;183:2669–74.PubMedCrossRefGoogle Scholar
  18. 18.
    Berin MC, Mayer L. Immunophysiology of experimental food allergy. Mucosal Immunol. 2009;2:24–32.PubMedCrossRefGoogle Scholar
  19. 19.
    Skripak JM, Sampson HA. Towards a cure for food allergy. Curr Opin Immunol. 2008;20:690–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Meresse B, Ripoche J, Heyman M, Cerf-Bensussan N. Celiac disease: from oral tolerance to intestinal inflammation, autoimmunity and lymphomagenesis. Mucosal Immunol. 2009;2:8–23.PubMedCrossRefGoogle Scholar
  21. 21.
    Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol. 1995;102:448–55.PubMedGoogle Scholar
  22. 22.
    Ergin A, Adam T, Bussow K, Thiel A, Sieper J, Duchmann R. Identification of the predominant antigenic epitopes in intestinal flora in IBD. Mucosal Immunol. 2008;1(Suppl 1):S19–23.PubMedCrossRefGoogle Scholar
  23. 23.
    Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007;117:514–21.PubMedCrossRefGoogle Scholar
  24. 24.
    Seldenrijk CA, Morson BC, Meuwissen SG, Schipper NW, Lindeman J, Meijer CJ. Histopathological evaluation of colonic mucosal biopsy specimens in chronic inflammatory bowel disease: diagnostic implications. Gut. 1991;32:1514–20.PubMedCrossRefGoogle Scholar
  25. 25.
    Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40:955–62.PubMedCrossRefGoogle Scholar
  26. 26.
    Budarf ML, Labbe C, David G, Rioux JD. GWA studies: rewriting the story of IBD. Trends Genet. 2009;25:137–46.PubMedCrossRefGoogle Scholar
  27. 27.
    Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008;8:458–66.PubMedCrossRefGoogle Scholar
  28. 28.
    Silverberg MS, Cho JH, Rioux JD, McGovern DP, Wu J, Annese V, et al. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet. 2009;41:216–20.PubMedCrossRefGoogle Scholar
  29. 29.
    Eksteen B, Liaskou E, Adams DH. Lymphocyte homing and its role in the pathogenesis of IBD. Inflamm Bowel Dis. 2008;14:1298–312.PubMedCrossRefGoogle Scholar
  30. 30.
    Fantini MC, Monteleone G, Macdonald TT. New players in the cytokine orchestra of inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:1419–23.PubMedCrossRefGoogle Scholar
  31. 31.
    Maloy KJ, Kullberg MC. IL-23 and Th17 cytokines in intestinal homeostasis. Mucosal Immunol. 2008;1:339–49.PubMedCrossRefGoogle Scholar
  32. 32.
    Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol. 2008;14:4280–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Stefanelli T, Malesci A, De La Rue SA, Danese S. Anti-adhesion molecule therapies in inflammatory bowel disease: touch and go. Autoimmun Rev. 2008;7:364–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Zimmerman NP, Vongsa RA, Wendt MK, Dwinell MB. Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:1000–11.PubMedCrossRefGoogle Scholar
  35. 35.
    Atreya R, Neurath MF. New therapeutic strategies for treatment of inflammatory bowel disease. Mucosal Immunol. 2008;1:175–82.PubMedCrossRefGoogle Scholar
  36. 36.
    Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology. 2009;136:1182–97.PubMedCrossRefGoogle Scholar
  37. 37.
    Coombes JL, Maloy KJ. Control of intestinal homeostasis by regulatory T cells and dendritic cells. Semin Immunol. 2007;19:116–26.PubMedCrossRefGoogle Scholar
  38. 38.
    Izcue A, Coombes JL, Powrie F. Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol. 2009;27:313–38.PubMedCrossRefGoogle Scholar
  39. 39.
    Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology. 2005;128:1868–78.PubMedCrossRefGoogle Scholar
  40. 40.
    Calado DP, Paixao T, Holmberg D, Haury M. Stochastic monoallelic expression of IL-10 in T cells. J Immunol. 2006;177:5358–64.PubMedGoogle Scholar
  41. 41.
    Kamanaka M, Kim ST, Wan YY, Sutterwala FS, Lara-Tejero M, Galan JE, et al. Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knockin tiger mouse. Immunity. 2006;25:941–52.PubMedCrossRefGoogle Scholar
  42. 42.
    Maynard CL, Harrington LE, Janowski KM, Oliver JR, Zindl CL, Rudensky AY, et al. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3− precursor cells in the absence of interleukin 10. Nat Immunol. 2007;8:931–41.PubMedCrossRefGoogle Scholar
  43. 43.
    Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, Holland G, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest. 1996;98:1010–20.PubMedCrossRefGoogle Scholar
  44. 44.
    Davidson NJ, Leach MW, Fort MM, Thompson-Snipes L, Kuhn R, Muller W, et al. T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med. 1996;184:241–51.PubMedCrossRefGoogle Scholar
  45. 45.
    Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263–74.PubMedCrossRefGoogle Scholar
  46. 46.
    Rennick D, Davidson N, Berg D. Interleukin-10 gene knock-out mice: a model of chronic inflammation. Clin Immunol Immunopathol. 1995;76:S174–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997;389:737–42.PubMedCrossRefGoogle Scholar
  48. 48.
    Kobayashi M, Kweon MN, Kuwata H, Schreiber RD, Kiyono H, Takeda K, et al. Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J Clin Invest. 2003;111:1297–308.PubMedGoogle Scholar
  49. 49.
    Autschbach F, Braunstein J, Helmke B, Zuna I, Schurmann G, Niemir ZI, et al. In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease. Am J Pathol. 1998;153:121–30.PubMedGoogle Scholar
  50. 50.
    Melgar S, Yeung MM, Bas A, Forsberg G, Suhr O, Oberg A, et al. Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis. Clin Exp Immunol. 2003;134:127–37.PubMedCrossRefGoogle Scholar
  51. 51.
    Niessner M, Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol. 1995;101:428–35.PubMedGoogle Scholar
  52. 52.
    Ebert EC, Panja A, Das KM, Praveen R, Geng X, Rezac C, et al. Patients with inflammatory bowel disease may have a transforming growth factor-beta-, interleukin (IL)-2- or IL-10-deficient state induced by intrinsic neutralizing antibodies. Clin Exp Immunol. 2009;155:65–71.PubMedCrossRefGoogle Scholar
  53. 53.
    Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet. 2008;40:1319–23.PubMedCrossRefGoogle Scholar
  54. 54.
    Anderson CA, Massey DC, Barrett JC, Prescott NJ, Tremelling M, Fisher SA, et al. Investigation of Crohn’s disease risk loci in ulcerative colitis further defines their molecular relationship. Gastroenterology. 2009; 136: 523–9 e3.Google Scholar
  55. 55.
    Franke A, Balschun T, Karlsen TH, Hedderich J, May S, Lu T, et al. Replication of signals from recent studies of Crohn’s disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet. 2008;40:713–5.PubMedCrossRefGoogle Scholar
  56. 56.
    Bhavsar MD, Amiji MM. Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther. 2008;15:1200–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Davidson NJ, Fort MM, Muller W, Leach MW, Rennick DM. Chronic colitis in IL-10-/- mice: insufficient counter regulation of a Th1 response. Int Rev Immunol. 2000;19:91–121.PubMedCrossRefGoogle Scholar
  58. 58.
    Duchmann R, Schmitt E, Knolle P, Meyer zum Buschenfelde KH, Neurath M. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol. 1996;26:934–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Hagenbaugh A, Sharma S, Dubinett SM, Wei SH, Aranda R, Cheroutre H, et al. Altered immune responses in interleukin 10 transgenic mice. J Exp Med. 1997;185:2101–10.PubMedCrossRefGoogle Scholar
  60. 60.
    Herfarth HH, Mohanty SP, Rath HC, Tonkonogy S, Sartor RB. Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. Gut. 1996;39:836–45.PubMedCrossRefGoogle Scholar
  61. 61.
    Lindsay J, Van Montfrans C, Brennan F, Van Deventer S, Drillenburg P, Hodgson H, et al. IL-10 gene therapy prevents TNBS-induced colitis. Gene Ther. 2002;9:1715–21.PubMedCrossRefGoogle Scholar
  62. 62.
    Nakase H, Okazaki K, Tabata Y, Ozeki M, Watanabe N, Ohana M, et al. New cytokine delivery system using gelatin microspheres containing interleukin-10 for experimental inflammatory bowel disease. J Pharmacol Exp Ther. 2002;301:59–65.PubMedCrossRefGoogle Scholar
  63. 63.
    Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000;289:1352–5.PubMedCrossRefGoogle Scholar
  64. 64.
    Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn’s disease. Gastroenterology. 2000;119:1473–82.PubMedCrossRefGoogle Scholar
  65. 65.
    Schreiber S, Heinig T, Thiele HG, Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology. 1995;108:1434–44.PubMedCrossRefGoogle Scholar
  66. 66.
    van Deventer SJ, Elson CO, Fedorak RN, Crohn’s Disease Study Group. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn’s disease. Gastroenterology. 1997;113:383–9.PubMedCrossRefGoogle Scholar
  67. 67.
    Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn’s disease. Gastroenterology. 2000;119:1461–72.PubMedCrossRefGoogle Scholar
  68. 68.
    Dejaco C, Reinisch W, Lichtenberger C, Waldhoer T, Kuhn I, Tilg H, et al. In vivo effects of recombinant human interleukin-10 on lymphocyte phenotypes and leukocyte activation markers in inflammatory bowel disease. J Investig Med. 2000;48:449–56.Google Scholar
  69. 69.
    Tilg H, van Montfrans C, van den Ende A, Kaser A, van Deventer SJ, Schreiber S, et al. Treatment of Crohn’s disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut. 2002;50:191–5.PubMedCrossRefGoogle Scholar
  70. 70.
    Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4:754–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991;174:561–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature. 1993;366:76–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515–48.PubMedCrossRefGoogle Scholar
  74. 74.
    Liu Z, Geboes K, Hellings P, Maerten P, Heremans H, Vandenberghe P, et al. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis. J Immunol. 2001;167:1830–8.PubMedGoogle Scholar
  75. 75.
    Sinclair NR. Immunoreceptor tyrosine-based inhibitory motifs on activating molecules. Crit Rev Immunol. 2000;20:89–102.PubMedGoogle Scholar
  76. 76.
    Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270:985–8.PubMedCrossRefGoogle Scholar
  77. 77.
    Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3:541–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192:303–10.PubMedCrossRefGoogle Scholar
  79. 79.
    Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med. 2000;192:295–302.PubMedCrossRefGoogle Scholar
  80. 80.
    Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322:271–5.PubMedCrossRefGoogle Scholar
  81. 81.
    Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24:2283–9.PubMedCrossRefGoogle Scholar
  82. 82.
    Johnston RL, Lutzky J, Chodhry A, Barkin JS. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci. 2008. doi:10.1007/s10620-008-0641-z
  83. 83.
    Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist. 2008;13(Suppl 4):2–9.PubMedCrossRefGoogle Scholar
  84. 84.
    Zalloua PA, Abchee A, Shbaklo H, Zreik TG, Terwedow H, Halaby G, et al. Patients with early onset of type 1 diabetes have significantly higher GG genotype at position 49 of the CTLA4 gene. Hum Immunol. 2004;65:719–24.PubMedCrossRefGoogle Scholar
  85. 85.
    Ahmedov G, Ahmedova L, Sedlakova P, Cinek O. Genetic association of type 1 diabetes in an Azerbaijanian population: the HLA-DQ, -DRB1*04, the insulin gene, and CTLA4. Pediatr Diabetes. 2006;7:88–93.PubMedCrossRefGoogle Scholar
  86. 86.
    Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003;423:506–11.PubMedCrossRefGoogle Scholar
  87. 87.
    Han S, Zhang S, Zhang W, Li R, Li Y, Wang Z, et al. CTLA4 polymorphisms and ophthalmopathy in Graves’ disease patients: association study and meta-analysis. Hum Immunol. 2006;67:618–26.PubMedCrossRefGoogle Scholar
  88. 88.
    Vaidya B, Imrie H, Perros P, Young ET, Kelly WF, Carr D, et al. The cytotoxic T lymphocyte antigen-4 is a major Graves’ disease locus. Hum Mol Genet. 1999;8:1195–9.PubMedCrossRefGoogle Scholar
  89. 89.
    Lee CS, Lee YJ, Liu HF, Su CH, Chang SC, Wang BR, et al. Association of CTLA4 gene A-G polymorphism with rheumatoid arthritis in Chinese. Clin Rheumatol. 2003;22:221–4.PubMedCrossRefGoogle Scholar
  90. 90.
    Lee YH, Choi SJ, Ji JD, Song GG. No association of polymorphisms of the CTLA-4 exon 1(+49) and promoter(−318) genes with rheumatoid arthritis in the Korean population. Scand J Rheumatol. 2002;31:266–70.PubMedCrossRefGoogle Scholar
  91. 91.
    Lei C, Dongqing Z, Yeqing S, Oaks MK, Lishan C, Jianzhong J, et al. Association of the CTLA-4 gene with rheumatoid arthritis in Chinese Han population. Eur J Hum Genet. 2005;13:823–8.PubMedCrossRefGoogle Scholar
  92. 92.
    Suppiah V, O’Doherty C, Heggarty S, Patterson CC, Rooney M, Vandenbroeck K. The CTLA4+49A/G and CT60 polymorphisms and chronic inflammatory arthropathies in Northern Ireland. Exp Mol Pathol. 2006;80:141–6.PubMedCrossRefGoogle Scholar
  93. 93.
    Suppiah V, Alloza I, Heggarty S, Goris A, Dubois B, Carton H, et al. The CTLA4 +49 A/G*G-CT60*G haplotype is associated with susceptibility to multiple sclerosis in Flanders. J Neuroimmunol. 2005;164:148–53.PubMedCrossRefGoogle Scholar
  94. 94.
    Machida H, Tsukamoto K, Wen CY, Narumi Y, Shikuwa S, Isomoto H, et al. Association of polymorphic alleles of CTLA4 with inflammatory bowel disease in the Japanese. World J Gastroenterol. 2005;11:4188–93.PubMedGoogle Scholar
  95. 95.
    Hou W, Xia B, Yuan A, Li J, Yang Z, Mao L. CTLA-4 gene polymorphisms in Chinese patients with ulcerative colitis. Inflamm Bowel Dis. 2005;11:653–6.PubMedCrossRefGoogle Scholar
  96. 96.
    Lankarani KB, Karbasi A, Kalantari T, Yarmohammadi H, Saberi-Firoozi M, Alizadeh-Naeeni M, et al. Analysis of cytotoxic T lymphocyte associated antigen 4 gene polymorphisms in patients with ulcerative colitis. J Gastroenterol Hepatol. 2006;21:449–53.PubMedCrossRefGoogle Scholar
  97. 97.
    Magyari L, Farago B, Bene J, Horvatovich K, Lakner L, Varga M, et al. No association of the cytotoxic T-lymphocyte associated gene CTLA4 +49A/G polymorphisms with Crohn’s disease and ulcerative colitis in Hungarian population samples. World J Gastroenterol. 2007;13:2205–8.PubMedGoogle Scholar
  98. 98.
    Rogler G, Hausmann M, Spottl T, Vogl D, Aschenbrenner E, Andus T, et al. T-cell co-stimulatory molecules are upregulated on intestinal macrophages from inflammatory bowel disease mucosa. Eur J Gastroenterol Hepatol. 1999;11:1105–11.PubMedCrossRefGoogle Scholar
  99. 99.
    Rugtveit J, Bakka A, Brandtzaeg P. Differential distribution of B7.1 (CD80) and B7.2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD). Clin Exp Immunol. 1997;110:104–13.PubMedCrossRefGoogle Scholar
  100. 100.
    Vuckovic S, Florin TH, Khalil D, Zhang MF, Patel K, Hamilton I, et al. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases. Am J Gastroenterol. 2001;96:2946–56.PubMedCrossRefGoogle Scholar
  101. 101.
    Buch MH, Vital EM, Emery P. Abatacept in the treatment of rheumatoid arthritis. Arthritis Res Ther. 2008;10(Suppl 1):S5.PubMedCrossRefGoogle Scholar
  102. 102.
    Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 2002;23:445–9.PubMedCrossRefGoogle Scholar
  103. 103.
    Belkaid Y, Oldenhove G. Tuning microenvironments: induction of regulatory T cells by dendritic cells. Immunity. 2008;29:362–71.PubMedCrossRefGoogle Scholar
  104. 104.
    Coombes JL, Siddiqui KR, Arancibia-Carcamo CV, Hall J, Sun CM, Belkaid Y, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med. 2007;204:1757–64.PubMedCrossRefGoogle Scholar
  105. 105.
    Siddiqui KR, Powrie F. CD103+ GALT DCs promote Foxp3+ regulatory T cells. Mucosal Immunol. 2008;1(Suppl 1):S34–8.PubMedCrossRefGoogle Scholar
  106. 106.
    Sun CM, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR, et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med. 2007;204:1775–85.PubMedCrossRefGoogle Scholar
  107. 107.
    Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 2003;24:242–8.PubMedCrossRefGoogle Scholar
  108. 108.
    Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4:762–74.PubMedCrossRefGoogle Scholar
  109. 109.
    Fallarino F, Vacca C, Orabona C, Belladonna ML, Bianchi R, Marshall B, et al. Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. Int Immunol. 2002;14:65–8.PubMedCrossRefGoogle Scholar
  110. 110.
    Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol. 2002;3:1097–101.PubMedCrossRefGoogle Scholar
  111. 111.
    Liebau C, Baltzer AW, Schmidt S, Roesel C, Karreman C, Prisack JB, et al. Interleukin-12 and interleukin-18 induce indoleamine 2, 3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma. Anticancer Res. 2002;22:931–6.PubMedGoogle Scholar
  112. 112.
    Wolf AM, Wolf D, Rumpold H, Moschen AR, Kaser A, Obrist P, et al. Overexpression of indoleamine 2, 3-dioxygenase in human inflammatory bowel disease. Clin Immunol. 2004;113:47–55.PubMedCrossRefGoogle Scholar
  113. 113.
    Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR. The indoleamine 2, 3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol. 2008;181:5396–404.PubMedGoogle Scholar
  114. 114.
    Molano A, Illarionov PA, Besra GS, Putterman C, Porcelli SA. Modulation of invariant natural killer T cell cytokine responses by indoleamine 2, 3-dioxygenase. Immunol Lett. 2008;117:81–90.PubMedCrossRefGoogle Scholar
  115. 115.
    Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med. 1999;189:1363–72.PubMedCrossRefGoogle Scholar
  116. 116.
    Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002;9:1069–77.PubMedCrossRefGoogle Scholar
  117. 117.
    Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2, 3-dioxygenase. Immunity. 2005;22:633–42.PubMedCrossRefGoogle Scholar
  118. 118.
    Lee GK, Park HJ, Macleod M, Chandler P, Munn DH, Mellor AL. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology. 2002;107:452–60.PubMedCrossRefGoogle Scholar
  119. 119.
    Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH. Cells expressing indoleamine 2, 3-dioxygenase inhibit T cell responses. J Immunol. 2002;168:3771–6.PubMedGoogle Scholar
  120. 120.
    Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998;281:1191–3.PubMedCrossRefGoogle Scholar
  121. 121.
    Gurtner GJ, Newberry RD, Schloemann SR, McDonald KG, Stenson WF. Inhibition of indoleamine 2, 3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology. 2003;125:1762–73.PubMedCrossRefGoogle Scholar
  122. 122.
    Harrington L, Srikanth CV, Antony R, Rhee SJ, Mellor AL, Shi HN, et al. Deficiency of indoleamine 2, 3-dioxygenase enhances commensal-induced antibody responses and protects against Citrobacter rodentium-induced colitis. Infect Immun. 2008;76:3045–53.PubMedCrossRefGoogle Scholar
  123. 123.
    Torres MI, Lopez-Casado MA, Lorite P, Rios A. Tryptophan metabolism and indoleamine 2, 3-dioxygenase expression in coeliac disease. Clin Exp Immunol. 2007;148:419–24.PubMedCrossRefGoogle Scholar
  124. 124.
    Greenberg GR. Antibiotics should be used as first-line therapy for Crohn’s disease. Inflamm Bowel Dis. 2004;10:318–20.PubMedCrossRefGoogle Scholar
  125. 125.
    Muller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry. 2007;12:988–1000.PubMedCrossRefGoogle Scholar
  126. 126.
    Bischoff SC, Mailer R, Pabst O, Weier G, Sedlik W, Li Z, et al. Role of serotonin in intestinal inflammation: knockout of serotonin reuptake transporter exacerbates 2,4,6-trinitrobenzene sulfonic acid colitis in mice. Am J Physiol Gastrointest Liver Physiol. 2009;296:G685–95.PubMedCrossRefGoogle Scholar
  127. 127.
    Leon-Ponte M, Ahern GP, O’Connell PJ. Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. Blood. 2007;109:3139–46.PubMedCrossRefGoogle Scholar
  128. 128.
    Nocito A, Dahm F, Jochum W, Jang JH, Georgiev P, Bader M, et al. Serotonin regulates macrophage-mediated angiogenesis in a mouse model of colon cancer allografts. Cancer Res. 2008;68:5152–8.PubMedCrossRefGoogle Scholar
  129. 129.
    Riley JL. PD-1 signaling in primary T cells. Immunol Rev. 2009;229:114–25.PubMedCrossRefGoogle Scholar
  130. 130.
    Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7–1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27:111–22.PubMedCrossRefGoogle Scholar
  131. 131.
    Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, Klemm M, et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci USA. 2004;101:10691–6.PubMedCrossRefGoogle Scholar
  132. 132.
    Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.PubMedCrossRefGoogle Scholar
  133. 133.
    Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203:883–95.PubMedCrossRefGoogle Scholar
  134. 134.
    Reynoso ED, Elpek KG, Francisco L, Bronson R, Bellemare-Pelletier A, Sharpe AH, et al. Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. J Immunol. 2009;182:2102–12.PubMedCrossRefGoogle Scholar
  135. 135.
    Kanai T, Totsuka T, Uraushihara K, Makita S, Nakamura T, Koganei K, et al. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J Immunol. 2003;171:4156–63.PubMedGoogle Scholar
  136. 136.
    Rhodes DA, Stammers M, Malcherek G, Beck S, Trowsdale J. The cluster of BTN genes in the extended major histocompatibility complex. Genomics. 2001;71:351–62.PubMedCrossRefGoogle Scholar
  137. 137.
    Stammers M, Rowen L, Rhodes D, Trowsdale J, Beck S. BTL-II: a polymorphic locus with homology to the butyrophilin gene family, located at the border of the major histocompatibility complex class II and class III regions in human and mouse. Immunogenetics. 2000;51:373–82.PubMedCrossRefGoogle Scholar
  138. 138.
    Vernet C, Boretto J, Mattei MG, Takahashi M, Jack LJ, Mather IH, et al. Evolutionary study of multigenic families mapping close to the human MHC class I region. J Mol Evol. 1993;37:600–12.PubMedCrossRefGoogle Scholar
  139. 139.
    Arnett HA, Escobar SS, Viney JL. Regulation of costimulation in the era of butyrophilins. Cytokine. 2009;46(3):370–5.PubMedCrossRefGoogle Scholar
  140. 140.
    Ye TZ, Gordon CT, Lai YH, Fujiwara Y, Peters LL, Perkins AC, et al. Ermap, a gene coding for a novel erythroid specific adhesion/receptor membrane protein. Gene. 2000;242:337–45.PubMedCrossRefGoogle Scholar
  141. 141.
    Malcherek G, Mayr L, Roda-Navarro P, Rhodes D, Miller N, Trowsdale J. The B7 homolog butyrophilin BTN2A1 is a novel ligand for DC-SIGN. J Immunol. 2007;179:3804–11.PubMedGoogle Scholar
  142. 142.
    Arnett HA, Escobar SS, Gonzalez-Suarez E, Budelsky AL, Steffen LA, Boiani N, et al. BTNL2, a butyrophilin/B7-like molecule, is a negative costimulatory molecule modulated in intestinal inflammation. J Immunol. 2007;178:1523–33.PubMedGoogle Scholar
  143. 143.
    Greenbaum S, Zhuang Y. Identification of E2A target genes in B lymphocyte development by using a gene tagging-based chromatin immunoprecipitation system. Proc Natl Acad Sci USA. 2002;99:15030–5.PubMedCrossRefGoogle Scholar
  144. 144.
    Nguyen T, Liu XK, Zhang Y, Dong C. BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation. J Immunol. 2006;176:7354–60.PubMedGoogle Scholar
  145. 145.
    Valentonyte R, Hampe J, Huse K, Rosenstiel P, Albrecht M, Stenzel A, et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet. 2005;37:357–64.PubMedCrossRefGoogle Scholar
  146. 146.
    He C, Hamon S, Li D, Barral-Rodriguez S, Ott J. MHC fine mapping of human type 1 diabetes using the T1DGC data. Diabetes Obes Metab. 2009;11(Suppl 1):53–9.PubMedCrossRefGoogle Scholar
  147. 147.
    Li Y, Pabst S, Lokhande S, Grohe C, Wollnik B. Extended genetic analysis of BTNL2 in sarcoidosis. Tissue Antigens. 2009;73:59–61.PubMedCrossRefGoogle Scholar
  148. 148.
    Konno S, Takahashi D, Hizawa N, Hattori T, Takahashi A, Isada A, et al. Genetic impact of a butyrophilin-like 2 (BTNL2) gene variation on specific IgE responsiveness to Dermatophagoides farinae (Der f) in Japanese. Allergol Int. 2009;58:29–35.PubMedCrossRefGoogle Scholar
  149. 149.
    Sato H, Spagnolo P, Silveira L, Welsh KI, du Bois RM, Newman LS, et al. BTNL2 allele associations with chronic beryllium disease in HLA-DPB1*Glu69-negative individuals. Tissue Antigens. 2007;70:480–6.PubMedCrossRefGoogle Scholar
  150. 150.
    Meyer T, Lauschke J, Ruppert V, Richter A, Pankuweit S, Maisch B. Isolated cardiac sarcoidosis associated with the expression of a splice variant coding for a truncated BTNL2 protein. Cardiology. 2008;109:117–21.PubMedCrossRefGoogle Scholar
  151. 151.
    Spagnolo P, Sato H, Grutters JC, Renzoni EA, Marshall SE, Ruven HJ, et al. Analysis of BTNL2 genetic polymorphisms in British and Dutch patients with sarcoidosis. Tissue Antigens. 2007;70:219–27.PubMedCrossRefGoogle Scholar
  152. 152.
    Mochida A, Kinouchi Y, Negoro K, Takahashi S, Takagi S, Nomura E, et al. Butyrophilin-like 2 gene is associated with ulcerative colitis in the Japanese under strong linkage disequilibrium with HLA-DRB1*1502. Tissue Antigens. 2007;70:128–35.PubMedCrossRefGoogle Scholar
  153. 153.
    Johnson CM, Traherne JA, Jamieson SE, Tremelling M, Bingham S, Parkes M, et al. Analysis of the BTNL2 truncating splice site mutation in tuberculosis, leprosy and Crohn’s disease. Tissue Antigens. 2007;69:236–41.PubMedCrossRefGoogle Scholar
  154. 154.
    Moller M, Kwiatkowski R, Nebel A, van Helden PD, Hoal EG, Schreiber S. Allelic variation in BTNL2 and susceptibility to tuberculosis in a South African population. Microbes Infect. 2007;9:522–8.PubMedCrossRefGoogle Scholar
  155. 155.
    Simmonds MJ, Heward JM, Barrett JC, Franklyn JA, Gough SC. Association of the BTNL2 rs2076530 single nucleotide polymorphism with Graves’ disease appears to be secondary to DRB1 exon 2 position beta74. Clin Endocrinol (Oxf). 2006;65:429–32.CrossRefGoogle Scholar
  156. 156.
    Orozco G, Eerligh P, Sanchez E, Zhernakova S, Roep BO, Gonzalez-Gay MA, et al. Analysis of a functional BTNL2 polymorphism in type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus. Hum Immunol. 2005;66:1235–41.PubMedCrossRefGoogle Scholar
  157. 157.
    Traherne JA, Barcellos LF, Sawcer SJ, Compston A, Ramsay PP, Hauser SL, et al. Association of the truncating splice site mutation in BTNL2 with multiple sclerosis is secondary to HLA-DRB1*15. Hum Mol Genet. 2006;15:155–61.PubMedCrossRefGoogle Scholar
  158. 158.
    Rybicki BA, Walewski JL, Maliarik MJ, Kian H, Iannuzzi MC. The BTNL2 gene and sarcoidosis susceptibility in African Americans and Whites. Am J Hum Genet. 2005;77:491–9.PubMedCrossRefGoogle Scholar
  159. 159.
    Price P, Santoso L, Mastaglia F, Garlepp M, Kok CC, Allcock R, et al. Two major histocompatibility complex haplotypes influence susceptibility to sporadic inclusion body myositis: critical evaluation of an association with HLA-DR3. Tissue Antigens. 2004;64:575–80.PubMedCrossRefGoogle Scholar
  160. 160.
    Rehaume LM, Hancock RE. Neutrophil-derived defensins as modulators of innate immune function. Crit Rev Immunol. 2008;28:185–200.PubMedGoogle Scholar
  161. 161.
    Wehkamp J, Koslowski M, Wang G, Stange EF. Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn’s disease. Mucosal Immunol. 2008;1(Suppl 1):S67–74.PubMedCrossRefGoogle Scholar
  162. 162.
    Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, Petras RE, et al. Reduced Paneth cell alpha-defensins in ileal Crohn’s disease. Proc Natl Acad Sci USA. 2005;102:18129–34.PubMedCrossRefGoogle Scholar
  163. 163.
    Wehkamp J, Schmid M, Fellermann K, Stange EF. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn’s disease. J Leukoc Biol. 2005;77:460–5.PubMedCrossRefGoogle Scholar
  164. 164.
    Voss E, Wehkamp J, Wehkamp K, Stange EF, Schroder JM, Harder J. NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem. 2006;281:2005–11.PubMedCrossRefGoogle Scholar
  165. 165.
    Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaffeler E, Schlee M, et al. NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal alpha-defensin expression. Gut. 2004;53:1658–64.PubMedCrossRefGoogle Scholar
  166. 166.
    Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nunez G, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005;307:731–4.PubMedCrossRefGoogle Scholar
  167. 167.
    Hormannsperger G, Clavel T, Hoffmann M, Reiff C, Kelly D, Loh G, et al. Post-translational inhibition of IP-10 secretion in IEC by probiotic bacteria: impact on chronic inflammation. PLoS ONE. 2009;4:e4365.PubMedCrossRefGoogle Scholar
  168. 168.
    Lan JG, Cruickshank SM, Singh JC, Farrar M, Lodge JP, Felsburg PJ, et al. Different cytokine response of primary colonic epithelial cells to commensal bacteria. World J Gastroenterol. 2005;11:3375–84.PubMedGoogle Scholar
  169. 169.
    Madsen KL. Inflammatory bowel disease: lessons from the IL-10 gene-deficient mouse. Clin Invest Med. 2001;24:250–7.PubMedGoogle Scholar
  170. 170.
    Smits HH, Engering A, van der Kleij D, de Jong EC, Schipper K, van Capel TM, et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol. 2005;115:1260–7.PubMedCrossRefGoogle Scholar
  171. 171.
    Carroll IM, Andrus JM, Bruno-Barcena JM, Klaenhammer TR, Hassan HM, Threadgill DS. Anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin 10-deficient mouse model of colitis. Am J Physiol Gastrointest Liver Physiol. 2007;293:G729–38.PubMedCrossRefGoogle Scholar
  172. 172.
    Di Giacinto C, Marinaro M, Sanchez M, Strober W, Boirivant M. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. J Immunol. 2005;174:3237–46.PubMedGoogle Scholar
  173. 173.
    Feighery LM, Smith P, O’Mahony L, Fallon PG, Brayden DJ. Effects of Lactobacillus salivarius 433118 on intestinal inflammation, immunity status and in vitro colon function in two mouse models of inflammatory bowel disease. Dig Dis Sci. 2008;53:2495–506.PubMedCrossRefGoogle Scholar
  174. 174.
    Hart AL, Lammers K, Brigidi P, Vitali B, Rizzello F, Gionchetti P, et al. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut. 2004;53:1602–9.PubMedCrossRefGoogle Scholar
  175. 175.
    Kim N, Kunisawa J, Kweon MN, Eog Ji G, Kiyono H. Oral feeding of Bifidobacterium bifidum (BGN4) prevents CD4(+) CD45RB(high) T cell-mediated inflammatory bowel disease by inhibition of disordered T cell activation. Clin Immunol. 2007;123:30–9.PubMedCrossRefGoogle Scholar
  176. 176.
    Lee HS, Han SY, Bae EA, Huh CS, Ahn YT, Lee JH, et al. Lactic acid bacteria inhibit proinflammatory cytokine expression and bacterial glycosaminoglycan degradation activity in dextran sulfate sodium-induced colitic mice. Int Immunopharmacol. 2008;8:574–80.PubMedCrossRefGoogle Scholar
  177. 177.
    Huynh HQ, deBruyn J, Guan L, Diaz H, Li M, Girgis S, et al. Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2009;15:760–8.PubMedCrossRefGoogle Scholar
  178. 178.
    Lorea Baroja M, Kirjavainen PV, Hekmat S, Reid G. Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. Clin Exp Immunol. 2007;149:470–9.PubMedGoogle Scholar
  179. 179.
    Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104:437–43.PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag, Basel/Switzerland 2009

Authors and Affiliations

  1. 1.Inflammation Research, AmgenSeattleUSA
  2. 2. Inflammation ResearchAmgenThousand OaksUSA

Personalised recommendations